EyePoint Announces LUGANO Trial Impacts For DURAVYU For Wet AMD
EyePoint reported mixed results from its LUGANO Phase 3 trial for wet AMD drug DURAVYU, missing the primary endpoint due to a small patient cohort but excelling in key secondary metrics. The company expects data from a second trial in late 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day